Why the top of the head is affected by hairloss more than other areas, and treatments such as surgery, medications like minoxidil, finasteride, and RU58841 to treat it.
Scalp tension from the occipitalis muscle is theorized to contribute to hairloss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
A user who had two hair transplants and is still concerned about their crown area, despite other people reassuring them that it looks normal. The advice given was to use Minoxidil, Finasteride, SMP, and to consider speaking with a therapist.
This user is considering using Finasteride and Minoxidil to treat their hairloss, with various opinions being shared about the effectiveness of each treatment. Others suggest that Micro-needling might also be an option for them.
A user is organizing a group buy for various compounds aimed at reversing hairloss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
The conversation is about the role of vitamin deficiencies in hairloss and the effectiveness of treatments like Minoxidil, finasteride, and RU58841. It concludes that while vitamins and nutrition are important, they are not the primary solution for androgenic alopecia.
A 21-year-old is using oral finasteride, minoxidil, and vitamins to address hairloss, showing some progress after two months. Many suggest shaving his head for a better appearance and easier progress tracking, while continuing the treatment and considering additional options like microneedling and Nizoral shampoo.
A user experienced significant hair regrowth using Minoxidil but started shedding hair after switching brands and adding treatments like Topical Finasteride and microneedling. They also faced increased hairloss after using Ketoconazole shampoo and are seeking advice on whether brand switching or the shampoo could be the cause.
The conversation discusses positive initial trial results for GT20029, a topical compound for hairloss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Balancing hormones, particularly testosterone and DHT, may prevent hairloss and slow aging. Treatments include finasteride, dutasteride, zinc, magnesium, collagen, and natural DHT-blocking shampoos.
A new study that found a single chemical could potentially be responsible for hairloss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hairloss.
AI advancements, like AlphaFold, are speeding up drug discovery for hairloss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hairloss communities.
Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hairloss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.
The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hairloss. Commenters note the impressive results and discuss application methods and safety precautions for family members.
The conversation discusses a person successfully using a combination of Minoxidil, finasteride, and other treatments for hairloss, resulting in significantly improved hair. Despite some criticism, many admire his dedication to health and anti-aging research.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hairloss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hair follicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hairloss.
The user used microneedling, zinc, vitamin D3, biotin, magnesium, saw palmetto, pumpkin seed oil, and a DHT-blocker shampoo with biotin for hairloss. They are considering adding minoxidil due to stagnation in progress.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
The individual had a hair transplant in Turkey with 4052 grafts, resulting in significant hair growth and increased confidence. They use finasteride, rosemary oil, and vitamins, and are pleased with the natural-looking results, encouraging others to consider similar treatments.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.